164 related articles for article (PubMed ID: 31774349)
1. An update on: molecular genetics of high-risk chronic lymphocytic leukemia.
Moia R; Patriarca A; Deambrogi C; Rasi S; Favini C; Kodipad AA; Schipani M; Gaidano G
Expert Rev Hematol; 2020 Feb; 13(2):109-116. PubMed ID: 31774349
[No Abstract] [Full Text] [Related]
2. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
3. Targeting p53 in chronic lymphocytic leukemia.
Moia R; Boggione P; Mahmoud AM; Kodipad AA; Adhinaveni R; Sagiraju S; Patriarca A; Gaidano G
Expert Opin Ther Targets; 2020 Dec; 24(12):1239-1250. PubMed ID: 33016796
[TBL] [Abstract][Full Text] [Related]
4. Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers.
Maher N; Mouhssine S; Matti BF; Alwan AF; Gaidano G
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373521
[TBL] [Abstract][Full Text] [Related]
5. Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.
Tam CS; Seymour JF; Roberts AW
Semin Oncol; 2016 Apr; 43(2):274-9. PubMed ID: 27040706
[TBL] [Abstract][Full Text] [Related]
6. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies.
Lukas M; Velten B; Sellner L; Tomska K; Hüellein J; Walther T; Wagner L; Muley C; Wu B; Oleś M; Dietrich S; Jethwa A; Bohnenberger H; Lu J; Huber W; Zenz T
Leukemia; 2020 Nov; 34(11):2934-2950. PubMed ID: 32404973
[TBL] [Abstract][Full Text] [Related]
7. Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53.
Christodoulopoulos G; Fotouhi N; Krajewski S; Reed JC; Alaoui-Jamali M; Panasci L
Cancer Lett; 1997 Dec; 121(1):59-67. PubMed ID: 9459175
[TBL] [Abstract][Full Text] [Related]
8. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
Johnston JB; Daeninck P; Verburg L; Lee K; Williams G; Israels LG; Mowat MR; Begleiter A
Leuk Lymphoma; 1997 Aug; 26(5-6):435-49. PubMed ID: 9389352
[TBL] [Abstract][Full Text] [Related]
9. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
Zhu HJ; Liu L; Fan L; Zhang LN; Fang C; Zou ZJ; Li JY; Xu W
Leuk Lymphoma; 2013 Dec; 54(12):2712-9. PubMed ID: 23517560
[TBL] [Abstract][Full Text] [Related]
10. Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.
Molica S; Tam C; Allsup D; Polliack A
Hematol Oncol; 2024 Jan; 42(1):e3238. PubMed ID: 37937506
[TBL] [Abstract][Full Text] [Related]
11. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
[TBL] [Abstract][Full Text] [Related]
12. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?
Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A
Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240
[TBL] [Abstract][Full Text] [Related]
13. Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment.
Condoluci A; Rossi D
Expert Rev Hematol; 2019 Feb; 12(2):89-98. PubMed ID: 30686074
[TBL] [Abstract][Full Text] [Related]
14. The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.
Ding W
Hematol Oncol Clin North Am; 2021 Aug; 35(4):739-759. PubMed ID: 34174984
[TBL] [Abstract][Full Text] [Related]
15. Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
Rossi D; Gerber B; Stüssi G
Leuk Lymphoma; 2017 Jul; 58(7):1548-1560. PubMed ID: 27808579
[TBL] [Abstract][Full Text] [Related]
16. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition.
Davids MS; Letai A; Brown JR
Leuk Lymphoma; 2013 Aug; 54(8):1823-5. PubMed ID: 23614795
[TBL] [Abstract][Full Text] [Related]
17. TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors.
Morabito F; Gentile M; Monti P; Recchia AG; Menichini P; Skafi M; Atrash M; De Luca G; Bossio S; Al-Janazreh H; Galimberti S; Salah Z; Morabito L; Mujahed A; Hindiyeh M; Dono M; Fais F; Cutrona G; Neri A; Tripepi G; Fronza G; Ferrarini M
Expert Opin Investig Drugs; 2020 Aug; 29(8):869-880. PubMed ID: 32551999
[TBL] [Abstract][Full Text] [Related]
18. Targeting Bcl-2 in CLL.
Rogalinska M; Kilianska ZM
Curr Med Chem; 2012; 19(30):5109-15. PubMed ID: 22856663
[TBL] [Abstract][Full Text] [Related]
19. The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis.
Molica S; Giannarelli D; Mirabelli R; Levato L; Shanafelt TD
Leuk Lymphoma; 2019 Jul; 60(7):1644-1649. PubMed ID: 30516079
[TBL] [Abstract][Full Text] [Related]
20. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
